SCHEDULE: RA Capital Discloses 9.9% Stake in Invivyd, Inc.
Schedule 13G Filing
RA Capital Management and its affiliates have disclosed a 9.9% beneficial ownership stake in Invivyd, Inc., totaling 21,338,288 shares.
Summary
- RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have reported beneficial ownership of 21,338,288 shares of Invivyd, Inc. common stock.
- This aggregate amount represents 9.9% of Invivyd, Inc.'s outstanding common stock.
- The ownership percentage is based on 209,377,291 shares outstanding as of August 22, 2025, plus 4,219,192 shares issuable from Pre-Funded Warrants.
- The RA Capital Healthcare Fund, L.P. directly holds 17,119,096 shares of common stock and Pre-Funded Warrants exercisable for up to 21,342,442 shares.
- A "Beneficial Ownership Blocker" provision in the Pre-Funded Warrants prevents exercise if it would result in beneficial ownership exceeding 9.99% of the common stock outstanding.
- RA Capital Management, L.P. serves as the investment adviser for the Fund and has sole power to vote and dispose of the securities held in the Fund's portfolio.
- Peter Kolchinsky and Rajeev Shah are controlling persons of RA Capital Management GP, LLC, the general partner of RA Capital.
- The Reporting Persons disclaim status as a "group" for purposes of Schedule 13G, and the securities were not acquired for the purpose of changing or influencing control of Invivyd, Inc.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or prospects. It simply reports a significant stake by an institutional investor.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by a specialized healthcare investment firm, RA Capital Management, in Invivyd, Inc., a biotechnology company. Such disclosures are common for institutional investors taking substantial positions in public companies, particularly in the biotech sector where strategic investments can signal confidence in a company's pipeline or market potential.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding a nearly 10% stake could be viewed positively, signaling confidence in the company. The presence of a beneficial ownership blocker ensures that this investor cannot easily exceed the 9.99% threshold without further regulatory scrutiny, which could be seen as a governance safeguard.
- Company Management: Awareness of a large, active investor like RA Capital Management may influence strategic decisions, though the filing explicitly states the stake is not for influencing control.
Key Dates
| Date | Description |
|---|---|
| 08/22/2025 | Date of event which required the filing of this statement (beneficial ownership threshold crossed). |
| 08/22/2025 | Date of Issuer's prospectus supplement disclosing 209,377,291 shares of common stock outstanding. |
| 08/29/2025 | Date of filing of the Schedule 13G statement. |
Keywords
Invivyd Inc, RA Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Pre-Funded Warrants, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.